Fate Therapeutics (FATE) Insider Trading & Ownership → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free FATE Stock Alerts $3.80 -0.07 (-1.81%) (As of 04/26/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Fate Therapeutics (NASDAQ:FATE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.04%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$166,023.60Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$278,392.35 Get FATE Insider Trade Alerts Want to know when executives and insiders are buying or selling Fate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FATE Insider Buying and Selling by Quarter Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. Fate Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/29/2024Edward J Dulac IIICFOSell1,849$5.00$9,245.00 1/9/2024Bahram ValamehrInsiderSell11,271$4.38$49,366.98 1/9/2024Cindy TahlGeneral CounselSell10,874$4.37$47,519.38 1/9/2024Edward J Dulac IIICFOSell7,028$4.37$30,712.36 1/9/2024J Scott WolchkoCEOSell14,391$4.37$62,888.67 12/26/2023Redmile Group, LlcDirectorBuy44,630$3.72$166,023.60 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/18/2023Edward J Dulac IIICFOSell4,718$2.80$13,210.40 8/4/2023Yuan XuDirectorSell632$3.71$2,344.72 7/5/2023Brian T PowlInsiderSell3,854$4.87$18,768.98 7/5/2023Edward J Dulac IIICFOSell5,182$4.83$25,029.06 6/14/2023Yuan XuDirectorSell3,460$5.58$19,306.80 (Data available from 1/1/2013 forward) FATE Insider Trading Activity - Frequently Asked Questions Who is on Fate Therapeutics's Insider Roster? The list of insiders at Fate Therapeutics includes Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu, and Yu-Waye Chu. Learn more on insiders at FATE. What percentage of Fate Therapeutics stock is owned by insiders? 5.04% of Fate Therapeutics stock is owned by insiders. Learn more on FATE's insider holdings. Which Fate Therapeutics insiders have been buying company stock? The following insiders have purchased FATE shares in the last 24 months: John Mendlein ($698,138.49), and Redmile Group, Llc ($440,023.60). How much insider buying is happening at Fate Therapeutics? Insiders have purchased a total of 215,009 FATE shares in the last 24 months for a total of $1,138,162.09 bought. Which Fate Therapeutics insiders have been selling company stock? The following insiders have sold FATE shares in the last 24 months: Bahram Valamehr ($625,258.40), Brian T Powl ($18,768.98), Cindy Tahl ($108,057.10), Edward J Dulac III ($269,685.61), J Scott Wolchko ($1,289,841.35), John Mendlein ($31,085.56), Mark Plavsic ($91,524.59), Shefali Agarwal ($18,409.49), Yuan Xu ($21,651.52), and Yu-Waye Chu ($16,635.24). How much insider selling is happening at Fate Therapeutics? Insiders have sold a total of 199,716 Fate Therapeutics shares in the last 24 months for a total of $2,490,917.84 sold. More Insider Trading Tools from MarketBeat Related Companies: Novavax Insider Selling Alector Insider Selling Taysha Gene Therapies Insider Selling Editas Medicine Insider Selling Allogene Therapeutics Insider Selling C4 Therapeutics Insider Selling Tourmaline Bio Insider Selling ProKidney Insider Selling Replimune Group Insider Selling Prime Medicine Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Pagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1The 5 Hottest CEO Stock Purchases So Far This Year3 Cheap Stocks that Insiders Bought in Q1 This page (NASDAQ:FATE) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
